US20040018192A1 - Integrin expression inhibitors - Google Patents

Integrin expression inhibitors Download PDF

Info

Publication number
US20040018192A1
US20040018192A1 US10/181,562 US18156202A US2004018192A1 US 20040018192 A1 US20040018192 A1 US 20040018192A1 US 18156202 A US18156202 A US 18156202A US 2004018192 A1 US2004018192 A1 US 2004018192A1
Authority
US
United States
Prior art keywords
group
compound
ring
nmr
ppm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/181,562
Other languages
English (en)
Inventor
Toshiaki Wakabayashi
Yasuhiro Funahashi
Naoko Hata
Taro Semba
Yuji Yamamoto
Toru Haneda
Takashi Owa
Akihiko Tsuruoka
Junichi Kamata
Tadashi Okabe
Keiko Takahashi
Kazumasa Nara
Shinichi Hamaoka
Norihiro Ueda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Assigned to EISAI CO., LTD. reassignment EISAI CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FUNAHASHI, YASUHIRO, HATA, NAOKO, SEMBA, TARO, WAKABAYASHI, TOSHIAKI
Publication of US20040018192A1 publication Critical patent/US20040018192A1/en
Priority to US11/097,218 priority Critical patent/US7834049B2/en
Priority to US12/797,806 priority patent/US20100267754A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to an integrin expression inhibitor, specifically, an integrin ⁇ 2 ⁇ 1, ⁇ 3 ⁇ 1, ⁇ 5 ⁇ 1, ⁇ 6 ⁇ 1, ⁇ v ⁇ 1, ⁇ v ⁇ 3 or ⁇ v ⁇ 5 expression inhibitor. Further it relates to an angiogenesis agent, an anticoagulant, an anticancer agent, a cancer metastasis suppressor, and an agent for treating retinal angiogenesis, diabetic retinopathy, inflammatory diseases, arterial sclerosis, psoriasis and osteoporosis, on the basis of integrin expression inhibitory action.
  • Integrin structurally consists of a heterodimer in which two types of sub-unit, namely, integrin ⁇ and integrin ⁇ are associated with each other by non-covalent binding. At least 16 types of ⁇ chains and 8 types of ⁇ chains have been found. A variety of molecular groups differing in ligand specificity are formed by the combination of these ⁇ and ⁇ chains and 22 types of integrins have been known. Integrin has a function as cell membrane receptor protein for an adhesive molecule of an animal cell, expresses on a cell membrane and participates in the adhesion between a cell and an extracellular matrix (ECM) or between cells.
  • ECM extracellular matrix
  • a signaling system in a cell starts moving and as a result, not only cell adhesion, but also cell evolution, cell proliferation, apoptosis, differentiation, cytoskeleton orientation, cell migration, histogenesis, cancer infiltration and metastasis, wound healing, blood coagulation and the like operate.
  • integrin ⁇ 2 ⁇ 1 of which the adhesive molecules are collagen and laminin participates in platelet aggregation, cancer infiltration and metastasis (HAYASHI Masao & MIYAMOTO Yasunori, PROTEIN, NUCLEIC ACID, ENZYME, Vol 44, pp130-135, (1999)) and angiogenesis (Donald R. Senger et al, Proc. Natl. Acad. Sci. USA, 94, 13612-13617, (1997)). It has come to be clarified that among these symptoms, the proliferation of cancer is closely related to angiogenesis.
  • an antiangiogenesis agent can inhibit and further reduce proliferative cancer and no resistant cancer is generated in a transplant cancer model and there is shown a correlation between angiogenesis and exacerbations of many solid cancers such as mammary cancer, prostatic cancer, lung cancer and colonic cancer in clinical examinations (T. Boem et al, Nature, 390 (27) 404-407, (1997)).
  • ⁇ v ⁇ 1 of which the adhesive molecules are fibronectin and vitronectin participates in the adhesion of a cancer cell to a substrate and ⁇ v ⁇ 3 of which the adhesive molecules are vitronectin and thrombospongin and ⁇ v ⁇ 5 of which the adhesive molecule is vitronectin participate in angiogenesis, cancer metastasis and the regeneration of bone (Shattil, S. J., Thromb. Haemost., 74, 149-155, (1995), Friedlander M, et al, Sceience, 270, 1500-1502, (1995)).
  • WO9950249 discloses the antagonist of integrin ⁇ v ⁇ 3, however there is no suggestion concerning the expression inhibitory action of integrin ⁇ v ⁇ 3.
  • JP-A 7-165708 and JP-A 8-231505 the same sulfonamide compound as that used in the present invention is disclosed; however, there is neither description nor hint concerning integrin expression inhibitory action.
  • WO9301182 discloses-anti-tumor agents utilizing a specific tyrosine kinase inhibitive action of a compound having an indole skeleton. These agents are indolylmethylene-2-indolinone compounds, which differ from that of the present invention.
  • WO964016 likewise discloses anti-tumor agents utilizing a specific tyrosine kinase inhibitory action of a compound having an indole skeleton.
  • these agents are 2-indolinone-3-methylene derivatives, which differ from that of the present invention.
  • An antiangiogenesis agent an anticancer agent, a cancer metastasis suppressor, an anticoagulant agent, and an agent for treating arterial sclerosis, psoriasis, retinal angiogenesis, diabetic retinopathy or inflammatory diseases on the basis of an integrin expression inhibitory action have not been known so far.
  • the present invention provides an agent for treating a disease against which an integrin expression inhibitiory action is effective. Specifically, it is an object of the present invention to provide an antiangiogenic agent, an anticancer agent, a cancer metastasis suppressor, an anticoagulant, and an agent for treating arterial sclerosis, psoriasis, osteoporosis, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, which comprises, as an active ingredient, a compound having an integrin expression inhibitory action. Another object of the present invention is to provide an integrin expression inhibitor comprising a sulfonamide compound.
  • the present invention relates to: 1. 1) an agent for treating arterial sclerosis, psoriasis, cancer, osteoporosis, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, 2) an anticoagulant, 3) a cancer metastasis suppressor or 4) an antiangiogenic agent on the basis of an integrin expression inhibitory action, 2.
  • an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the formula (I), a pharmacologically acceptable salt thereof or a hydrate of them:
  • B represents a C6-C10 aryl ring or a 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated
  • K represents a single bond, —CH ⁇ CH— or —(CR 4b R 5b ) m b — (where R 4b and R 5b are the same as or different from each other and each represents hydrogen atom or a C1-C4 alkyl group; and m b means an integer of 1 or 2)
  • R 1 represents hydrogen atom or a C1-C6 alkyl group
  • Z represents a single bond or —CO—NH—
  • R represents a C6-C10 aryl ring or a 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively
  • an integrin expression inhibitor comprising, as an active ingredient, the sulfonamide compound as described in 3., a pharmacologically acceptable salt thereof or a hydrate of them, wherein R is indole, quinoline or isoquinoline, 5.
  • an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the formula (I a ), a pharmacologically acceptable salt thereof or a hydrate of them:
  • the A a ring a monocyclic or bicyclic aromatic ring which may have a substituent;
  • the B a ring represents an optionally substituted 6-membered cyclic unsaturated hydrocarbon or unsaturated 6-membered heterocycle containing one nitrogen atom as a heteroatom;
  • the C a ring represents an optionally substituted 5-membered heterocycle containing 1 or 2 nitrogen atoms;
  • R 1a represents hydrogen atom or a C1-C6 alkyl group;
  • W a represents a single bond or —CH ⁇ CH—;
  • Y a represents carbon atom or nitrogen atom; and
  • Z a represents —N(R 2a )— (wherein R 2a means hydrogen atom or a lower alkyl group) or nitrogen atom, respectively), 6.
  • an integrin expression inhibitor comprising, as an active ingredient, the sulfonamide compound as described in 5., a pharmacologically acceptable salt thereof or a hydrate of them, wherein W a is a single bond, 7.
  • an integrin expression inhibitor comprising, as an active ingredient, the sulfonamide compound as described in 5., a pharmacologically acceptable salt thereof or a hydrate of them, wherein W a is a single bond; Z a is —NH—; and Y a is carbon atom, 8. the integrin expression inhibitor comprising, as an active ingredient, a the sulfonamide compound as described in any of 5., 6.
  • a pharmacologically acceptable salt thereof or a hydrate of them wherein the B a ring is an optionally substituted benzene or pyridine, 9. an integrin expression inhibitor comprising, as an active ingredient, the sulfonamide compound as described in any of 5. to 8., a pharmacologically acceptable salt thereof or a hydrate of them, wherein the C a ring is an optionally substituted pyrrole, 10.
  • an integrin expression inhibitor comprising, as an active ingredient, the sulfonamide compound as described in 5., a pharmacologically acceptable salt thereof or a hydrate of them, wherein the A a ring is a benzene or pyridine which may have a substituent; the B a ring is benzene which may have a substituent; the C a ring is pyrrole which may have a substituent; W a is a single bond; and Z a is —NH—, 11.
  • an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide-containing heterocyclic compound represented by the formula (I b ), a pharmacologically acceptable salt thereof or a hydrate of them:
  • a b represents hydrogen atom, a halogen atom, hydroxyl group, a C1-C4 alkyl or alkoxy group which may be substituted with a halogen atom, cyano group, —(CO) k b NR 2b R 3b (wherein R 2b and R 3b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group which may be substituted with a halogen atom; and k b means 0 or 1), a C2-C4 alkenyl or alkynyl group which may have a substituent, or a phenyl or phenoxy group which may have a substituent selected from the following group A; B b means an aryl group or monocyclic heteroaryl group which may have a substituent selected from the following group A, or the following formula:
  • ring Q b means an aromatic ring which may have one or two nitrogen atoms; and the ring M b means a C5-C12 unsaturated monocycle or heterocycle having a double bond in common with the ring Q b .
  • the ring may have 1 to 4 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom, the ring Q b and the ring M b may jointly have nitrogen atom, and the ring Q b and the ring M b may have a substituent selected from the following group A);
  • K b means a single bond or —(CR 4b R 5b )m b — (wherein R 4b and R 5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and m b means an integer of 1 or 2);
  • Group A a halogen atom, hydroxyl group, a C1-C4 alkyl or alkoxy group which may be substituted with a halogen atom, cyano group, —R 8b R 9b N(NH) p b — (wherein R 8b and R 9b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group which may be substituted with a halogen atom; and p b means 0 or 1.
  • R 8b and R 9b may form a 5- or 6-membered ring together with the nitrogen atom to which they are bound, and the ring may further contain nitrogen atom, oxygen atom or sulfur atom, and also may have a substituent.
  • an aminosulfonyl group which may be substituted with a mono- or di-C1-C4 alkyl group, a C1-C8 acyl group which may have a substituent, a C1-C4 alkyl-S(O) s b —C1-C4 alkylene group (wherein s b means an integer of 0, 1 or 2), a phenylsulfonylamino group which may have a C1-C4 alkyl or a substituent, —(CO) q b NR10b R 11b (wherein R 10b and R 11b are the same as or different from each other and each means hydrogen atom, or a C1-C4 alkyl group which may substituted with an amino group
  • an integrin expression inhibitor comprising, as an active ingredient, the sulfonamide-containing heterocyclic compound as described in 11., a pharmacologically acceptable salt thereof or a hydrogen of them, wherein U b and V b are ⁇ C(D b )—(wherein D b has the same meaning as above) or nitrogen atom, 13.
  • an integrin expression inhibitor comprising, as an active ingredient, the sulfonamide-containing heterocyclic compound as described in 11. or 12., a pharmacologically acceptable salt thereof or a hydrate of them, wherein Z b is a single bond, 14.
  • an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide-containing heterocyclic compound as described in any of 11.
  • an integrin expression inhibitor comprising, as an active ingredient, the sulfonamide-containing heterocyclic compound as described in any of 11.
  • a b represents a halogen atom, a C1-C4 alkyl group or alkoxy group which may be substituted with a halogen atom, cyano group, —(CO) r b NR 12b R 13b (wherein R 12b and R 13b are the same as or different from each other and each represents hydrogen atom or a C1-C4 alkyl group which may be substituted with a halogen atom; and r b means 0 or 1) or a C2-C4 alkenyl or alkynyl group which may have a substituent, 16.
  • an integrin expression inhibitor comprising, as an active ingredient, the sulfonamide-containing heterocyclic compound as described in any of 11. to 15., a pharmacologically acceptable salt thereof or a hydrate of them, wherein only one of T b , U b , V b , W b , X b and Y b is nitrogen atom, 17.
  • an integrin expression inhibitor comprising, as an active ingredient, the sulfonamide-containing heterocyclic compound as described in any of 11. to 16., a pharmacologically acceptable salt thereof or a hydrate of them, wherein only one of T b , W b and y b is nitrogen atom, 18.
  • an integrin expression inhibitor comprising, as an active ingredient, the sulfonamide compound as described in any of 5. to 17., a pharmacologically acceptable salt thereof or a hydrate of them, wherein the integrin is integrin ⁇ 2, ⁇ 3, ⁇ 5, ⁇ 6, ⁇ v, ⁇ 1, ⁇ 3, ⁇ 4 or ⁇ 5, 19.
  • an integrin expression inhibitor comprising, as an active ingredient, the sulfonamide compound as described in any of 5. to 17., a pharmacologically acceptable salt thereof or a hydrate of them, wherein the integrin is integrin ⁇ 2 ⁇ 1, ⁇ 3 ⁇ 1, ⁇ 5 ⁇ 1, ⁇ 6 ⁇ 1, ⁇ v ⁇ 1, ⁇ v ⁇ 3 or ⁇ v ⁇ 5, 20.
  • the present invention provides a method for preventing, treating or improving a disease against which an integrin expression inhibition is effective, by administering a pharmacologically effective dose of the compound represented by any of formulae (I), (Ia) and (Ib), a pharmacologically acceptable salt thereof or a hydrate of them to a patient.
  • the present invention provides use of the compound represented by any of formulae (I), (Ia) and (Ib), a pharmacologically acceptable salt of the compound or hydrate of them, for producing an agent for preventing, treating or improving a disease against which integrin expression inhibition is effective.
  • the diseases against which integrin expression inhibition is effective include arterial sclerosis, psoriasis, cancer, osteoporosis, retinal angiogenesis, diabetic retinopathy and inflammatory diseases.
  • the agent for preventing, treating or improving a disease against which an integrin expression inhibition is effective includes an agent for treating arterial sclerosis, psoriasis, cancer, osteoporosis, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant agent, a cancer metastasis suppressor and an antiangiogenesis agent.
  • the C6-C10 aryl ring or 6-membered to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated means an aromatic hydrocarbon group having 6 to 10 carbon atoms or a 6-membered to 10-membered aromatic heterocycle containing at least one atom among nitrogen atom, oxygen atom and sulfur atom as a heteroatom, and may have one or more substituents on the ring and a part of the ring may be saturated.
  • benzene pyridine, pyrimidine, pyrazine, pyridazine, naphthalene, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, indole, isoindole, indolizine, indazole, benzofuran, benzothiophene, benzoxazole, benzimidazole, benzopyrazole, benzothiazole, 4,5,6,7-tetrahydroindole, 1,2,3,4-tetrahydroisoquinoline, 2,3-dihydrobenzofuran, indane, tetralone, indoline, isoindoline, chroman and tetralin.
  • the above-mentioned aromatic ring may have 1 to 3 substituents. In the case where plural substituents are present, these substituents may be the same or different.
  • substituents may include an amino group which may be substituted with a lower alkyl group or lower cycloalkyl group, a lower alkyl group, a lower alkoxy group, hydroxyl group, nitro group, mercapto group, cyano group, a lower alkylthio group, a halogen group, a group represented by the formula -a a -b a (wherein a a means a single bond, —(CH 2 ) k a —, —O—(CH 2 ) k a —, —S—(CH 2 ) k a — or —N(R 3a )—(CH 2 ) k a — (wherein k a means an integer of 1 to 5; and R 3a means hydrogen atom or a lower alkyl
  • the “monocyclic or bicyclic aromatic ring which may have a substituent” represented by the A a ring is an aromatic hydrocarbon or an aromatic heterocycle containing at least one of nitrogen atom, oxygen atom and sulfur atom, wherein 1 to 3 substituents may exist on the ring.
  • main aromatic rings contained in the A a ring include pyrrole, pyrazole, imidazole, thiophene, furan, thiazole, oxazole, benzene, pyridine, pyrimidine, pyrazine, pyridazine, naphthalene, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, indole, isoindole, indolizine, indazole, benzofuran, benzothiophene, benzoxazole, benzimidazole, benzopyrazole and benzothiazole.
  • the above-mentioned aromatic ring may have 1 to 3 substituents. When plural substituents are present, these substituents may be the same or different.
  • substituent may include an amino group which may be substituted with a lower alkyl group or a lower cycloalkyl group, lower alkyl group, lower alkoxy group, hydroxyl group, nitro group, mercapto group, cyano group, lower alkylthio group, halogen group, a group represented by the formula -a a -b a (wherein a a means a single bond, —(CH 2 ) k a —, —O—(CH 2 ) k a —, —S—(CH 2 ) k a — or —N(R 3a )—(CH 2 ) k a —; k a means an integer of 1 to 5; R 3a means hydrogen atom or a lower alkyl group; and ba represents —CH 2 -d
  • the amino group when the amino group is substituted with two alkyl groups, these alkyl groups may be bound together to form a 5- to 6-membered ring.
  • the A a ring is a nitrogen-containing heterocycle having hydroxyl group or mercapto group, the A a ring may have the form of an oxo group or thioxo group by allowing these groups to form a resonance structure.
  • the “6-membered cyclic unsaturated hydrocarbon or the unsaturated six-membered heterocycle which contains one nitrogen atom as a heteroatom, which may have a substituent” represented by the B a ring is a benzene or pyridine a part of which may be hydrogenated and may have one or two substituents on the ring. When two substituents are present, these substituents may be the same or different.
  • the “five-membered heterocycle which may have a substituent and contains one or two nitrogen atoms” represented by the C a ring is pyrrole, pyrazole or imidazole a part of which may be hydrogenated and may have one or two substituents on the ring. When two substituents are present, these substituents may be the same or different.
  • Examples of the substituent which the B a ring and the C a ring may have may include a halogen group, cyano group, a lower alkyl group, a lower alkoxy group, hydroxyl group, oxo group, the formula —C(O)-r a (wherein r a means hydrogen atom, an amino group which may be substituted with a lower alkyl group, a lower alkyl group, a lower alkoxy group or hydroxyl group), an amino group which may be substituted with a lower alkyl group and trifluoromethyl group.
  • Examples of the lower alkyl group in the definiteion of the substituent which R 1a , R 2a , and the A a , B a and C a rings may have in the above formula (I a ) mean a linear or branched alkyl group having 1 to 6 carbon atoms, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group (amyl group), isopentyl group, neopentyl group, tert-pentyl group, 1-methylbutyl group, 2-methylbutyl group, 1,2-dimethylpropyl group, n-hexyl group, isohexyl group, 1-methylpentyl group, 2-methylpentyl group, 3-methylpentyl group, 1,1-dimethylbutyl
  • methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group and isobutyl group may be proposed.
  • methyl group, ethyl group, n-propyl group and isopropyl group are most preferable groups.
  • Examples of the lower cycloalkyl group in the definiteion of the substituent which the Aa ring may have include a cyclopropyl group, cyclopentyl group and cyclohexyl group.
  • the lower alkoxy group in the definiteion of the substituent which the A a ring, the B a ring and the C a ring may have means a lower alkoxy groups derived from the above-mentioned lower alkyl groups such as methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butoxy group, isobutoxy group and tert-butoxy group.
  • methoxy group and ethoxy group may be given as most preferable examples.
  • examples of the halogen atom include fluorine atom, chlorine atom and bromine atom.
  • substituents particularly preferable examples include 1) N-(3-cyano-4-methyl-1H-indole-7-yl)-3-cyanobenzenesulfonamide; 2) N-(3-cyano-4-methyl-1H-indole-7-yl)-6-chloro-3-pyridinesulfonamide; 3) N-(3-bromo-5-methyl-1H-indole-7-yl)-4-sulfamoylbenzenesulfonamide; 4) N-(5-bromo-3-chloro-1H-indole-7-yl)-6-amino-3-pyridinesulfonamide; 5) N-(3-bromo-5-methyl-1H-indole-7-yl)-3-cyanobenzenesulfonamide; 6) N-(4-bromo-1H-indole-7-yl)-4-cyanobenzenesulfonamide; 7) N-(4-(4-methyl-1H-
  • the sulfonamide derivative represented by the above formula (I a ) forms a salt in combination with an acid or a base.
  • the present invention also involves salts of the compound (I a ).
  • the salt of an acid include inorganic acid salts such as hydrochloride, hydrobromide and sulfate, and salts of organic acids such as acetic acid, lactic acid, succinic acid, fumaric acid, maleic acid, citric acid, benzoic acid, methanesulfonic acid and p-toluenesulfonic acid.
  • the salt of a base may include inorganic salts such as sodium salts, potassium salts and calcium salts and salts of organic bases such as triethylamine, arginine and lysine.
  • the “aromatic ring which may have one or two nitrogen atoms” represented by the ring Q b means an aromatic hydrocarbon or a 6-membered aromatic heterocycle having one or two nitrogen atoms.
  • Examples of primary aromatic rings included in the ring Q b include benzene, pyridine, pyrimidine, pyrazine and pyridazine.
  • the ring M represented by the term “means a C5-C12 unsaturated monocycle or multi-cycle, which may have 1 to s4 heteroatoms selected from nitrogen atom, oxygen atom and sulfur atom” means a monocycle or a multi-cycle having a double bond together with the ring Q b and specifically means aromatic hydrocarbons such as benzene and naphthalene, unsaturated hydrocarbons such as cyclopentene, cyclohexene, cycloheptene, cyclooctene, cyclopentadiene, cycloheptadiene and cyclooctadiene, and unsaturated heterocycles such as tetrahydropyridine, pyrrole, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, pyrazole, imidazole, triazole, pyridine, pyrimidine, pyrazine, pyridazin
  • the term “the ring Q b possesses one nitrogen atom together with the ring M b ” means the case where the nitrogen atom is present at the position where both rings are condensed.
  • Examples of the ring formed in this manner include indazolizine, imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine and pyrazolo[1,5-a]pyrimidine.
  • the C1-C4 alkyl group in R 1b , R 4b and R 5b or in the “C1-C4 alkyl group which may be substituted with a halogen atom” in A b , D b , R 1b , R 2b , R 3b , R 6b , R 7b , R 8b , R 9b , R 10b , R 11b , R 12b , R 13b , R 14b , R 15b , G 1b , G 2b and the A group means a linear or branched alkyl group having 1 to 4 carbons atoms.
  • methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group and tert-butyl group may be proposed.
  • the term “may be substituted with a halogen atom” means that the alkyl group may be substituted with a halogen atom selected from fluorine atom, chlorine atom, bromine atom and iodine atom.
  • monofluoromethyl group for example, monofluoromethyl group, monochloromethyl group, difluoromethyl group, trifluoromethyl group, 1- or 2-monofluoromethyl group, 1- or 2-monochloroethyl group, 1- or 2-monobromoethyl group, 1,2-difluoroethyl group, 1,2-dichloroethyl group, 1,1,2,2,2-pentafluoroethyl group and 3,3,3-trifluoropropyl group may be proposed.
  • Preferable examples among these groups include monofluoromethyl group, difluoromethyl group, trifluoromethyl group, 1- or 2-monofluoroethyl group, 1,2-difluoroethyl group and 1,1,2,2,2-pentafluoroethyl group.
  • the C1-C4 alkoxy group in the “C1-C4 alkoxy group which may be substituted with a halogen atom” in A a , D b and the group A means a linear or branched alkoxy group having 1 to 4 carbon atoms.
  • methoxy group, ethoxy group, n-propyloxy group, isopropyloxy group, n-butyloxy group, isobutyloxy group, sec-butyloxy group and tert-butyloxy group may be proposed.
  • halogen atom means that the alkoxy group may be substituted with a halogen atom selected from fluorine atom, chlorine atom, bromine atom and iodine atom.
  • a halogen atom selected from fluorine atom, chlorine atom, bromine atom and iodine atom.
  • monofluoromethoxy group, difluoromethoxy group, trifluoromethoxy group, 1- or 2-monofluoroethoxy group, 1- or 2-monochloroethoxy group, 1- or 2-monobromoethoxy group, 1,2-difluoroethoxy group, 1,1,2,2,2-pentafluoroethoxy group and 3,3,3-trifluoropropyloxy group may be proposed.
  • preferable examples include monofluoromethoxy group, difluoromethoxy group, trifluoromethoxy group, 1- or 2-monofluoroethoxy group, 1,2-difluoroethoxy group and 1,1,2,2,2-pentafluoroethoxy group.
  • the C2-C4 alkenyl or alkynyl group appeared in A b and D b means an alkenyl or alkynyl group having 2 to 4 carbon atoms.
  • vinyl group, allyl group, 2- or 3-butenyl group, 1,3-butadienyl group, ethynyl group, 2-propynyl group, 2-methylethynyl group and 2- or 3-butynyl group may be proposed.
  • the heteroaryl group means a monocycle or multi-cycle having one or two or more of nitrogen atom, oxygen atom and sulfur atom.
  • pyrrolyl, imidazolyl group, pyrazolyl group, triazolyl group, furyl group, thienyl group, oxazolyl group, isoxazolyl group, thiazolyl group, isothiazolyl group, thiadiazolyl group, pyridyl group, pyrimidyl group, pyrazyl group, indolyl group, indolizinyl group, benzoimidazolyl group, benzothiazolyl group, benzoxazolyl group, quinolinyl group, isoquinolinyl group, quinazolinyl group and phthalazinyl group may be proposed.
  • R 8b and R 9b may form a 5- or 6-membered ring together with the nitrogen atom to which they are bound, and the ring may further contain nitrogen atom, oxygen atom or sulfur atom” in the definition of R 8b and R 9b means that R 8b and R 9b form pyrrolidinyl group, piperidinyl group, morpholino group, thiomorpholino group, piperazinyl group etc. together with the nitrogen atom to which they are bound.
  • the aminosulfonyl group which may be substituted with a mono- or di-C1-C4 alkyl group, C1-C4 alkyl-S(O) a b -C1-C4-alkylene group, or phenylsulfonylamino group which may have a C1-C4 alkyl group or a substituent and a C1-C4 alkyl group which may be substituted with a C1-C4 alkyl group in the defineition of A group means the same alkyl group as above, and examples of the alkylene group may include methylene group, ethylene group, propylene group, butylene group, methylmethylene group, 1- or 2-methylethylene group, 1-, 2- or 3-methylpropylene group and dimethylmethylene group.
  • the C1-C8 alkanoyl group means, for example, formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group and benzoyl group.
  • the protective group in the term “an amino group which may have a protective group” appeared in J b of the present invention may be any group as far as it is known as a protective group in the usual organic synthesis and no particular limitation is imposed on the protective group.
  • benzyloxycarbonyl group, t-butoxycarbonyl group, formyl group, acetyl group, chloroacetyl group, 2,2,2-trichloroethyl group, benzylidene group, benzhydryl group and trityl group may be proposed.
  • the protective group in the carboxy group which may have a protective group and the protective group of the carboxy group in R 16b may be any group as far as it is known as a protective group in the usual organic synthesis and no particular limitation is imposed on the protective group.
  • methyl group, ethyl group, propyl group, isopropyl group, t-butyl group, methoxymethyl group, 2,2,2-trichloroethyl group, pivaloyloxymethyl group and benzyl group may be proposed.
  • the substituent in the term “may have a substituent” means the above-mentioned halogen atom, C1-C4 alkyl group or alkoxy group which may be substituted with a halogen atom, hydroxyl group, hydroxy C1-C4 alkyl group, amino group which may be substituted with a mono- or di-C1-C4 alkyl group, C2-C4 alkenyl or alkynyl group, cyano group, C1-C8 acyl group, aminosulfonyl group which may be substituted with a mono or di C1-C4 alkyl group, carboxy group, C1-C4 alkoxycarbonyl group and carbamoyl group which may be substituted with a mono- or di-C1-C4 alkyl group.
  • the sulfonamide-containing heterocyclic compound represented by the above formula (I b ) occasionally forms a salt in combination with an acid or a base.
  • the present invention also includes salts of the compound (I b ).
  • the salt of an acid include inorganic acid salts such as hydrochloride, hydrobromide and sulfate and salts of organic acids such as acetic acid, lactic acid, succinic acid, fumaric acid, maleic acid, citric acid, benzoic acid, methanesulfonic acid and p-toluenesulfonic acid.
  • inorganic salts such as sodium salts, potassium salts and calcium salts and salts of organic bases such as triethylamine, arginine and lysine may be given.
  • the present invention also includes compounds showing an antiangiogenesis action and produced from the present compound following in vivo metabolism such as oxidation, reduction, hydrolysis and conjugation. Also, the present invention further includes compounds producing the compound of the present invention following in vivo metabolism such as oxidation, reduction and hydrolysis.
  • the compound (I a ) according to the present invention can be produced by various methods. For example, several methods among these methods are specifically disclosed in the publications of JP-A 7-165708 and JP-A 8-231505.
  • the compound (I a ) of the present invention may be produced using various methods. Among these methods, typical methods are shown as follows.
  • the Ba a ring represents a 6-membered unsaturated hydrocarbon or unsaturated 6-membered heterocycle which contains on nitrogen atom as a heteroatom, which may have a protected or unprotected substituent;
  • the Ca a ring a 5-membered ring which may have a protected or unprotected substituent and contains one or two nitrogen atoms;
  • X a , Y a and Z a have the same meanings as above.
  • Examples of the reactive derivative of the sulfonic acid (II a ) may include reactive derivatives usually used frequently such as sulfonyl halides, sulfonic acid anhydrides and N-sulfonylimidazolides. Particularly preferable examples are sulfonyl halides.
  • a solvent which dissolves raw materials and does not react with these raw materials with ease.
  • pyridine, tetrahydrofuran, dioxane, benzene, ethyl ether, dichloromethane and dimethylformamide, or a mixed solvent using two or more solvents selected from these solvents may be utilized.
  • the reaction in the case where a free acid appears with the progress of the reaction as shown in the case of using a sulfonyl halide, the reaction is preferably run in the presence of a proper deoxidizer. Therefore, the use of a basic solvent such as pyridine is particularly preferable. When a neutral solvent is used, a basic substance such as an alkali carbonate and an organic tertiary amine may be added. It is needless to say that usable solvents are not limited to these exemplified solvents.
  • the reaction generally proceeds at room temperature, the raw materials may be cooled or heated according to the need. The reaction time is generally 10 minutes to 20 hours but is selected according to the type of raw material and the reaction temperature.
  • a sulfonamide derivative or sulfonate derivative (I a ) having a free hydroxyl group or amino group can be obtained by a usual deprotecting method such as acid treatment, alkali treatment and catalytic reduction, as required.
  • halogenating agent N-chlorosuccinimide, N-bromosuccinimide, 1,3-dibromo-5,5-dimethylhydantoin, N-bromoacetamide, chlorine and bromine may be proposed.
  • an alkyl chloride compound such as dichloromethane, chloroform and carbon tetrachloride, or an aromatic chloride such as chlorobenzene and dichlorobenzene is generally used, and a water-soluble solvent such as dimethylformamide, dioxane, pyridine and acetonitrile may be also used.
  • a water-soluble solvent such as dimethylformamide, dioxane, pyridine and acetonitrile may be also used.
  • the reaction temperature differs depending on the types of halogenating agent and substrate, it is usually run at ⁇ 50° C. to 100° C.
  • a sulfonamide derivative or sulfonate derivative (I a ) having a free hydroxyl group or amino group can be obtained by a usual deprotecting method such as acid treatment, alkali treatment and catalytic reduction, as required.
  • an oxime or an acid amide is first synthesized from an aldehyde or a carboxylic acid used as a starting material and then reacted with a dehydrating agent without isolating it.
  • a dehydrating agent those used in a usual method of synthesizing nitrile, for example, acetic acid anhydride, thionyl chloride, phosphorous oxychloride, selenium dioxide and 1,3-dicyclohexylcarbodiimide may be given.
  • the solvent to be used in the reaction examples include pyridine, ethyl ether, benzene, dimethylformamide, carbon tetrachloride, acetonitrile and tetrahydrofuran, or a mixed solvent of two or more solvents selected from these solvents may be utilized.
  • the reaction temperature differs depending on the types of dehydrating agent and substrate, the reaction is usually run at ⁇ 50° C. to 150° C.
  • a sulfonamide derivative or sulfonate derivative (I a ) having a free hydroxyl group or amino group can be obtained using a usual deprotecting method such as acid treatment, alkali treatment and catalytic reduction, as required.
  • the Ab a ring represents a monocyclic or bicyclic aromatic ring which has a substituent convertible into amino group by reduction and may also have a protected or unprotected substituent; and the Ba a ring, the Ca a ring, W a , X a , Y a and Z a have the same meanings as above) with a reducing agent.
  • a substituent convertible into amino group by reduction nitro group, nitroso group, hydroxyamino group and azo group may be exemplified.
  • a nitro group-reducing method which is commonly examples of the reducing method, catalytic reduction using, as a catalyst, palladium-carbon and platinum oxide and reduction using zinc, iron or tin with an acid may be given.
  • the catalytic reduction may be usually carried out under normal pressure or under pressure in an organic solvent such as methanol, tetrahydrofuran or dimethylformamide.
  • a sulfonamide derivative or sulfonate derivative (I a ) having a free hydroxyl group can be obtained using a usual deprotecting method such as acid treatment, alkali treatment and catalytic reduction, as required.
  • the Ac a ring means a monocyclic or bicyclic aromatic ring which has a dissociable group on the ring or in a substituent, and may also have a protected or unprotected substituent; and the Ba a ring, the Ca a ring, W a , X a , Y a and Z a have the same meanings as above) with a nucleophilic agent.
  • the leaving group may include a halogen group, methanesulfonyloxy group and p-toluenesulfonyloxy group.
  • the nucleophilic agent may include amines, alcohols and thiols.
  • these compounds may have the form of a salt of an alkali metal or the like upon reaction.
  • a solvent which dissolves raw materials and does not react with these materials with ease is desirable.
  • tetrahydrofuran, dioxane, dimethylformamide or water may be utilized.
  • the reaction temperature differs depending on the type of substrate, the reaction is usually run at ⁇ 50° C. to 150° C.
  • a sulfonamide derivative or sulfonate derivative (I a ) having a free hydroxyl group or amino group can be obtained by a usual deprotecting method such as acid treatment, alkali treatment and catalytic reduction, as required.
  • the raw material compound (II a ) and its reactive derivative include known compounds and novel compounds.
  • these compounds may be produced by applying a method of synthesizing a known compound which has been already reported or by using a combination of these known methods.
  • a novel sulfonyl chloride may be produced by a method obtained by applying synthetic methods described in Chem. Ber., 90, 841 (1957), J. Med. Chem., 6, 307 (1963), J. Chem. Soc.(c), 1968, 1265, Chem. Lett., 1992, 1483, J. Am. Chem. Soc., 59, 1837 (1937), J. Med. Chem., 23, 1376 (1980), J. Am. Chem. Soc., 70, 375 (1948), J. Am. Chem. Soc., 78, 2171 (1956) etc.
  • the raw material compound (III a ) includes known compounds and novel compounds.
  • H—X a — represents an amino group H 2 N— in the raw material compound (III a )
  • an H 2 N body (III a ) can be obtained by reducing the nitro compound by using a nitro group-reducing method which is usually used.
  • the reducing methods include catalytic reduction using a palladium-carbon catalyst and reduction using a zinc powder-hydrochloric acid.
  • the catalytic reduction may be usually carried out under normal pressure or under pressure in an organic solvent such as methanol, tetrahydrofuran and dimethylformamide.
  • H—X a — means hydroxyl group (HO—) in the raw material compound (III a )
  • a HO compound (III a ) can be obtained by diazotizing the above amino compound and then hydrolyzing the resulting product.
  • these compounds may be produced by applying a method of synthesizing a known compound which has been already reported or by using a combination of these known methods.
  • a novel compound may be produced by applying the methods described in Can. J. Chem., 42, 1235 (1964), Chem. Abst., 59, 8855f (1963), Tetrahedron Lett., 30, 2129 (1989) etc. through, for example, the following route.
  • Q a s mean the same or different substituents; G a means a halogen group; and t a means an integer from 0 to 2.
  • Q a , G a and t a have the same meanings as above; and DPPA means diphenylphosphorylazide.
  • Q a , G a and t a have the same meanings as above; and DDQ means 2,3-dichloro-5,6-dicyano-1,4-benzoquinone.
  • the compound (I b ) of the present invention may be produced by various methods. Among them, typical methods are as follows.
  • a b , B b , T b , U b , V b , W b , X b and T b have the same meanings as above. It may be produced by reacting the sulfonic acid represented by the formula (V b ) or its reactive derivative with the compound represented by the formula (VI b ).
  • reactive derivatives generally utilized frequently such as sulfonyl halides, sulfonic acid anhydrides and N-sulfonylimidazolides may be proposed.
  • a particularly preferable example is a sulfonyl halide.
  • the solvent to be used in the reaction those which dissolve the raw material and do not react with the raw material with ease are desirable.
  • pyridine, tetrahydrofuran, dioxane, benzene, ethyl ether, dichloromethane and dimethylformamide, or a mixed solvent of two or more solvents selected from these may be utilized.
  • the reaction in the case where a free acid appears with the progress of the reaction as shown in the case of using a sulfonyl halide, the reaction is preferably run in the presence of a proper deoxidizer. Therefore, the use of a basic solvent such as pyridine is particularly preferable. When a neutral solvent is used, a basic substance such as an alkali carbonate and an organic tertiary amine may be added. It is needless to say that usable solvents are not limited to these exemplified solvents.
  • this reaction generally proceeds at room temperature, the raw materials may be cooled or heated according to the need. The reaction time is generally 10 minutes to 20 hours but is optionally selected according to the type of raw material and the reaction temperature.
  • a sulfonamide derivative (VII b ) having a free hydroxyl group or amino group can be obtained using a usual deprotecting method such as acid treatment, alkali treatment and catalytic reduction, as required.
  • L b means chlorine atom or bromine atom
  • R 17b represents a C1-C4 alkyl group or benzyl group
  • a b , B b , T b , U b , V b , W b , X b and T b have the same meanings as above.
  • the reaction is run in water or a water-miscible non-reactive solvent such as tetrahydrofuran and acetone in the presence of abase such as sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium methoxide and sodium hydride.
  • abase such as sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium methoxide and sodium hydride.
  • the reaction is run at a temperature from 0° C. up to 100° C. and preferably about 20 to 30° C.
  • Another preferable reaction is attained by a method in which an amine represented by the formula (XI b ) is reacted with a carbamate represented by the formula (XII b ) obtained by reacting a sulfonamide represented by the formula (IX b ) with a haloformate represented by the formula (XIII b ).
  • reaction between the sulfonamide represented by the formula (IX b ) with the haloformate represented by the formula (XIII b ) is run in a non-reactive solvent such as acetone, tetrahydrofuran and methyl ethyl ketone in the presence of an acid scavenger such as potassium carbonate, sodium carbonate, potassium hydroxide and sodium hydroxide.
  • a non-reactive solvent such as acetone, tetrahydrofuran and methyl ethyl ketone
  • an acid scavenger such as potassium carbonate, sodium carbonate, potassium hydroxide and sodium hydroxide.
  • reaction between the carbamate represented by the formula (XII b ) and the amine represented by the formula (XI b ) is run in an inert and high-boiling point solvent such as dioxane, toluene and diglym under heating at a temperature from about 50° C. to a refluxing temperature.
  • an inert and high-boiling point solvent such as dioxane, toluene and diglym under heating at a temperature from about 50° C. to a refluxing temperature.
  • the amine compound represented by the formula (VI b ) or (XI b ) as the raw material of the sulfonamide or sulfonylurea-containing heterocyclic compound of the present invention may be produced using a combination of known methods.
  • quinoline and isoquinoline derivatives may be produced in the following production steps.
  • a b and G 2b have the same meanings as above.
  • R 18b has the same meaning as above; and R 19b means a C1-C4 alkyl group.
  • R 18b and E 2b have the same meanings as above;
  • R 20b and R 21b respectively means hydrogen atom or a C1-C4 alkyl group;
  • R 22b represents a C1-C4 alkoxy group, a phenoxy group or phenyl group which may have a substituent, cyano group or an amino group which may be substituted with a mono- or di-C1-C4 alkyl group;
  • E 3b represents hydrogen atom, a halogen atom, a C1-C4 alkoxy group, a phenoxy group or phenyl group which may have a substituent, cyano group or an amino group which may be substituted with a mono- or di-C1-C4 alkyl group.
  • the compound of the present invention When the compound of the present invention is used as drugs, it is administered orally or parenterally.
  • the dose of the compound differs depending on the degree of symptoms, the ages, sexes, weights and a difference in sensitivity of patients, the administration method, the time of administration, administration interval, the features of drug preparations, prescription and types of drug preparations, the types of active ingredients etc. and no particular limitation is imposed on the dose.
  • the dose is generally 10 to 6000 mg, preferably about 50 to 4000 mg and more preferably 100 to 3000 mg per day for an adult and the drug is generally administered at the defined dose in one to three protons a day.
  • a filler and further, as required, a binder, a disintegrator, a lubricant, a colorant and a flavoring agent were added to a base drug and then the mixed drugs are made into tablets, coated tablets, granules, fine granules, powders or capsule agents.
  • the filler for example, lactose, cornstarch, saccharose, glucose, sorbitol, crystalline cellulose or silicon dioxide; as the binder, for example, polyvinyl alcohol, ethyl cellulose, methyl cellulose, gum arabic, hydroxypropyl cellulose or hydroxypropylmethyl cellulose; as the lubricant, for example, magnesium stearate, talc or silica; as the colorant, those permitted to be added to drugs; and as the flavor, cocoa powder, menthol, aromatic acid, peppermint oil, borneol, cinnamon powder etc. is used.
  • These tablets and granules may be provided with sugar coating or gelatin coating and in addition, may be properly coated as required.
  • a pH regulator, a buffer, a suspending agent, a solubilizer, a stabilizer, an isotonic agent, a preservative etc. are added to a base drug according to the need and the mixture is then made into intravenous injections, subcutaneous injections or intramuscular injections by a usual method. At this time, these injections are occasionally made into freeze-dried products.
  • suspending agent may include methyl cellulose, polysorbate 80, hydroxyethyl cellulose, gum arabic, traganth powder, carboxymethyl cellulose sodium and polyoxyethylene sorbitan monolaurate.
  • solubilizer may include polyoxyethylene hydrogenated castor oil, polysorbate 80, nicotinic acid amide, polyoxyethylene sorbitan monolaurate, macrogol and castor oil fatty acid ethyl ester.
  • examples of stabilizers may include sodium sulfite and sodium methasulfite; and examples of the preservative may include methyl paraoxybenzoate, ethyl paraoxybenzoate, sorbic acid, phenol, cresol and chlorocresol.
  • FIG. 1 shows, on the upper side, the results obtained by measuring the quantity of integrin expression after 48 hours when using a compound A (untreated and 0.05 ⁇ g/ml) for human umbilical venous endothelial cells and, on the lower side, T/C expressed as % as to the effect of the compound A as compared with the untreated case.
  • FIG. 2 shows the integrin expression inhibitory action of the compound A (0.05 ⁇ g/ml) on a human colonic cancer cell line (HCT116-C9) after 48 hours: the effect of the compounds A as compared with the untreated case is expressed as T/C (%).
  • FIG. 3 shows the integrin expression inhibitory action of the compound A with a high concentration (0.5 ⁇ g/ml and 5 ⁇ g/ml) on a human normal fibroblast cell line (WI38) after 48 hours: the effect of the compounds A as compared with the untreated case is expressed as T/C (%).
  • FIG. 4 shows the integrin ⁇ 2 expression inhibitory action of each compound (0.5 ⁇ g/ml) on human umbilical cord endothelial cells (HUVEC) after 48 hours: the rate of the quantity of integrin ⁇ 2 expressed as compared with the untreated case is expressed as (%). (The name of each compound is shown by Synthetic Example number.)
  • FITC connective anti-mouse IgG antibody was added to the cells, which was then allowed to stand for 30 minutes and washed again. Next, the cells were fixed and the amount of antibody connected per cell was measured as the amount of FITC by using a flow cytometer.
  • the compound A inhibited the expression of integrins ⁇ 2, ⁇ 3, ⁇ 5, ⁇ 6, ⁇ v, ⁇ 1, ⁇ 3 and ⁇ 5 on the surface of the cell in a concentration of 0.05 ⁇ g/ml.
  • the compound A inhibited the expression of integrins ⁇ 2, ⁇ 3, ⁇ 5, ⁇ 6, ⁇ 1 and ⁇ 4 in a concentration of 0.05 ⁇ g/ml and in a concentration of 0.5 ⁇ g/ml.
  • the inhibition degree of angiogenesis which was observed when aorta pieces of rat were incubated in collagen was defined as an antiangiogenic effect. That is, the aorta excised from male rat of Sprague-Dawley strain (10-12 weeks age) was washed with a Hanks' solution so that fat tissues around there were removed minutely. The aorta was incised to prepare pieces of 2 mm square and they were allowed to stand in a 24-well plate holding the endothelial cells upside.
  • the medium was again exchanged with 500 ⁇ l of MCDB 131 medium containing the test compound and, at the stage of the 7th day from the initiation of addition of the test compound, numbers of capillaries formed around the aorta were counted under a microscope.
  • the solution containing the test compound was prepared in a three-fold dilution system where 10 ⁇ g/ml was the highest concentration.
  • Inhibiting rate was calculated from the following formula and 50% inhibiting concentration (IC 50 ) for each test compound was determined.
  • Inhibiting Rate (%) ( C ⁇ T )/ C ⁇ 100
  • T Numbers of capillaries when a compound was added
  • the compound according to the present invention showed an IC 50 value of 0.05 to 3 ⁇ g/ml.
  • 0.4 ml of type I collagen was added to a 24-well plate and solidified.
  • Human umbilical venous endothelial cells (HUVEC) of 8 ⁇ 10 4 in number were seeded on the collagen and cultured overnight by using endotherial cells culture solution (Gibco BRL) containing 10 ng/ml EGF and 20 ng/ml bFGF.
  • endotherial cells culture solution Gibco BRL
  • the supernatant was removed and then 0.4 ml of the same collagen was overlaid.
  • a culture solution containing 1.5 ml of the compound A was further added and the cells were cultured for 4 days. Thereafter, the area of the formed tube was measured quantitatively by image analysis.
  • the IC 50 of the compound A was 0.12 ⁇ g/ml. It was confirmed that an ⁇ 2 antibody had the same effect, but this effect was not observed in the case of an ⁇ 5 antibody.
  • the above activity was evaluated using a method obtained by improving a mouse air capsule method (Sakamoto et al., Cancer Res., 1, 55-57, 1986) in part. Specifically, a millipore ring (Nippon Millipore) was sealed using a 0.22 ⁇ m membrane filter (HAWPO, Nippon Millipore) to form a chamber. 1 ⁇ 10 7 human colic cancer cell strains (WiDr) which were suspended in a phosphoric acid buffer solution were sealed into the chamber. Next, an air capsule was formed on a subcutaneous site of the backside of a C57 Black female mouse of 6 to 8 weeks age and the foregoing chamber was transplanted to the air capsule.
  • a millipore ring Naippon Millipore
  • HAWPO 0.22 ⁇ m membrane filter
  • WiDr human colic cancer cell strains
  • the compound A was orally administered after about 6 hours passed after the transplantation was finished and afterwards administered in sequence once a day for 3 days.
  • the erythrocytes of the mouse that was labeled with 51 Cr was injected from the tail vein 4 days after the chamber was transplanted. After one hour, the skin at the portion which was in contact with the chamber was resected under anesthesia. After the skin was frozen, only the portion which was in contact with the chamber was separated precisely to measure the amount of blood by using ⁇ counter. Then, a value obtained by subtracting the amount of blood measured in the case of the chamber including no cancer cell from the above amount of blood was determined as the amount of angiogenesis.
  • the control groups consisted of 10 mice per group and the compound-administrated groups consisted of 5 mice per group.
  • Human umbilical venous endothelial cells (HUVEC) of 5 ⁇ 10 5 in number were seeded in a 75 cm 2 cell culture bottle and then cultured using an EGM medium (Sanko Junyaku) at 37° C. in a CO 2 incubator. Then, after 3 hours, the EGM medium was exchanged for the same medium including a compound of 0.5 ⁇ g/ml, which was then cultured for further 48 hours. Next, the cells were collected and washed with a bovine serum albumin-containing phosphate buffer solution and the above buffer solution containing an anti-human integrin ⁇ 2 mouse antibody was added thereto and the solution was allowed to stand at 4° C. for 30 minutes.
  • EGM medium Sudo Junyaku
  • FITC connective anti-mouse IgG antibody was added to the cells, which was then allowed to stand for 30 minutes and washed again. Next, the cells were fixed and the amount of antibody connected per cell was measured as the amount of FITC by using a flow cytometer. The inhibitory action of each compound is shown by the ratio (%) of the amount of expression to that obtained in the untreated compound. The name of each compound is shown by Synthetic Example number.
  • each compound inhibited the expression of integrin ⁇ 2 on the surface of the cell in a concentration of 0.5 ⁇ g/ml.
  • the extract was successively washed with an aqueous saturated sodium bicarbonate, water and brine, and dried over magnesium sulfate.
  • the solvent was evaporated, and to the residue was added a mixed solution of diethyl ether and hexane.
  • the crystals were collected by filtration, to give 16.0 g of the title compound.
  • the product was dissolved in 160 ml of 1,3-dimethyl-2-imidazolidinone, 716 mg (3.24 mmol) of basic copper carbonate was added thereto, and the mixture was stirred at 185° C. for 2 hours.
  • the reaction solution was poured into water, the insoluble matters were filtered off and the filtrate was extracted with ethyl acetate.
  • the organic layer was successively washed with water and brine, dried over magnesium sulfate and concentrated. Then, the residue was purified by silica gel column chromatography, to give 4.50 g of the title compound.
  • a toluene solution (150 g) containing 3.4 M sodium bis(2-methoxyethoxy)aluminum hydride was added thereto at ⁇ 40° C., followed by stirring at room temperature for one hour.
  • Water (120 ml) was added thereto, the insoluble matters were collected by filtration and the filtrate was extracted with ethyl ether.
  • the organic layer was successively washed with an aqueous saturated sodium bicarbonate and brine, dried over magnesium sulfate and concentrated. Then, the residue was dissolved in ethyl ether, and 50 ml of a 4 N-hydrochloric acid/ethyl acetate solution was added thereto. The resulting precipitates were collected by filtration, to give 14.5 g of the title compound.
  • N-Chlorosuccinimide was treated in a tetrahydrofuran-dimethylformamide solution containing the compound of Production Example 31, to give the title compound.
  • Melting point started decomposing gradually from a temperature close to 148° C. and decomposed rapidly at 163 to 164° C. (recrystallized from ethanol/n-hexane).
  • Melting point started coloring partially in a black color from a temperature close to 220° C. and decomposed gradually from a temperature close to 240° C. (recrystallized from ethanol-n-hexane).
  • reaction solution was poured into ice-water, and the precipitates were collected by filtration and washed with water. The precipitates were dissolved in tetrahydrofuran, dried over magnesium sulfate and then concentrated to dryness, to give 3.5 g of the title compound.
  • the reaction solution was added to an acetic acid solution saturated with sulfur dioxide (solution obtained by saturating 30 ml of acetic acid with sulfur dioxide and then adding 0.97 g of cupric chloride ⁇ dihydrate thereto) under ice-cooling with stirring. After stirring at room temperature for 40 minutes, the reaction solution was poured into ice-water and the mixture was saturated with sodium chloride. The mixture was extracted with ethyl acetate, and the extract was dried over magnesium sulfate and then concentrated to dryness, to give 1.7 g of the title compound.
  • the title compound was also obtained by hydrogenating 3-chloro-7-nitro-1H-indole at normal temperature under normal pressure in the presence of a platinum-carbon catalyst.
  • the title compound was obtained by chlorinating 6-chloro-N-(1H-indole-7-yl)-3-pyridinesulfonamide obtained by reacting 6-chloro-3-pyridinesulfonyl chloride and the compound of Production Example 2a in the same manner as in Example 1a.
  • the reaction mixture was adjusted to pH about 14 by adding a 1N aqueous sodium hydroxide and then to pH about 2 by adding 1N hydrochloric acid, and then extracted by adding ethyl acetate thereto.
  • the organic layer was washed with brine, dried over magnesium sulfate and concentrated.
  • the residue was purified by silica gel column chromatography, to give 1.45 g of the title compound.
  • Melting point started coloring partially in a black color from a temperature close to 220° C. and decomposed gradually from a temperature close to 240° C. (recrystallized from ethanol/n-hexane).
  • Melting point started coloring from a temperature close to 282° C. and gradually decomposed (recrystallized from ethanol/ethyl ether).
  • Melting point started coloring from the temperature close to 210° C. and decomposed at 213 to 215° C. (recrystallized from ethyl acetate/n-hexane).
  • the product was reduced using zinc powder/concentrated hydrochloric acid in 10 ml of methanol according to a conventional method, to give 75 mg of 4-amino-5-chloro-N-(3-chloro-1H-indole-7-yl)-2-thiophenesulfonamide.
  • 72 mg (0.20 mmol) of the product was dissolved in 2 ml of tetrahydrofuran, and 18 ⁇ l of pyridine and 38 mg (0.2 mmol) of 5-methyl-3-pyridinesulfonyl chloride were added thereto.
  • the organic layer was separated by adding ethyl acetate and 1N hydrochloric acid thereto. It was successively washed with water, an aqueous sodium bicarbonate and water, dried over magnesium sulfate and concentrated. Then, the residue was purified by silica gel column chromatography, to give 82 mg of the title compound.
  • Tributylvinyltin (2.8 ml) and tetrakistriphenylphosphinepalladium (171 mg) were added to a toluene solution (20 ml) containing 2.0 g (7.4 mmol) of ethyl-4,8-dichloroquinoline-3-carboxylate obtained in the same manner as in Production Example 4b, followed by stirring for 2 hours under heating under reflux.
  • the reaction solution was filtered through Celite and the filtrate was concentrated. Then, the residue was purified by silica gel chromatography, to give 1.92 g of the title compound.
  • N-Bromosuccinimide 39.2 g was added to a methylene chloride solution (300 ml) containing 26.67 g (0.2 mol) of 1,2,3,4-tetrahydroisoquinoline under ice-cooling over 20 minutes. After stirring for 40 minutes, an aqueous 30% sodium hydroxide solution (130 ml) was added to the reaction solution. The organic layer was washed with water and then extracted with a 10% aqueous hydrochloric acid (200 ml). The aqueous layer was washed with methylene chloride, basified with an aqueous ammonia, and then extracted with methylene chloride. The extract was dried over magnesium sulfate and then evaporated. The resulting residue was distilled (about 16 mmHg, 120° C.), to give 21.5 g of the title compound as an oil.
  • 6-Aminoisoquinoline (3.348 g, Synthesis, 733 (1975)) was dissolved in pyridine (30 ml). To the mixture was added 4-toluenesulfonyl chloride (5.13 g), followed by stirring at room temperature overnight. Water was added thereto, and the mixture was extracted with ethyl acetate. The extract was washed with brine and dried over anhydrous magnesium sulfate. The solvent was evaporated and the residue was recrystallized from ethanol, to give the title compound (5.958 g, 85%) as pale yellow crystals.
  • the residue was basified by adding an aqueous saturated sodium bicarbonate in an ice bath, and then the mixture was extracted with ethyl acetate. The extract was washed with brine and dried over anhydrous magnesium sulfate, and the solvent was evaporated. The residue was purified by silica gel column, to give crude crystals of the title compound (1.630 g, 49.40%). The crystals were recrystallized from ethanol, to give the title compound as colorless crystals.
  • N-(3-Nitrophenethyl)phthalimide obtained in Production Example 26b was suspended in ethanol (150 ml). To the mixture was added hydrazine (5.7 ml), followed by heating under reflux for one hour. The reaction solution was once dissolved completely, but crystals again precipitated. The crystals were filtered off and washed with cooled ethanol. Then, the solvent was evaporated, to give the title compound (5.559 g, 99%) as a yellow oil.
  • N-Acetyl-N-(3-nitrophenethyl)amine (2.1 g, Production Example 28b) was dissolved in ethanol (40 ml). To the mixture were added an iron powder (2.25 g), ammonium acetate (4.3 g) and water (20 ml), followed by heating under reflux for 1.5 hours. Solid was filtered off and washed with ethanol, and then the filtrate was partially evaporated. The residue was extracted with ethyl acetate, washed with brine and dried over anhydrous magnesium sulfate. The solvent was evaporated, to give the title compound (1.723 g, 96%) as a yellow oil.
  • N-Acetyl-N-(3-aminophenethyl)amine (1.7 g, Production Example 29b) was dissolved in pyridine (5 ml). Under ice-cooling, ethyl chloroformate (1.4 ml) was added dropwise thereinto, followed by stirring at room temperature for one hour. Then, the mixture was ice-cooled again and water was added thereto. The mixture was extracted with ethyl acetate, and the extract was washed with brine and dried over anhydrous magnesium sulfate. The solvent was evaporated, to give the title compound (2.358 g, 97%) as a yellow oil.
US10/181,562 2000-02-03 2001-02-01 Integrin expression inhibitors Abandoned US20040018192A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/097,218 US7834049B2 (en) 2000-02-03 2005-04-04 Integrin expression inhibitor
US12/797,806 US20100267754A1 (en) 2000-02-03 2010-06-10 Integrin expression inhibitor

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000-26080 2000-02-03
JP2000026080 2000-02-03
JP2000402084 2000-12-28
JP2000-402084 2000-12-28
PCT/JP2001/000713 WO2001056607A1 (fr) 2000-02-03 2001-02-01 Inhibiteurs de l'expression de l'integrine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/097,218 Continuation US7834049B2 (en) 2000-02-03 2005-04-04 Integrin expression inhibitor

Publications (1)

Publication Number Publication Date
US20040018192A1 true US20040018192A1 (en) 2004-01-29

Family

ID=26584780

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/181,562 Abandoned US20040018192A1 (en) 2000-02-03 2001-02-01 Integrin expression inhibitors
US11/097,218 Expired - Fee Related US7834049B2 (en) 2000-02-03 2005-04-04 Integrin expression inhibitor
US12/797,806 Abandoned US20100267754A1 (en) 2000-02-03 2010-06-10 Integrin expression inhibitor

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/097,218 Expired - Fee Related US7834049B2 (en) 2000-02-03 2005-04-04 Integrin expression inhibitor
US12/797,806 Abandoned US20100267754A1 (en) 2000-02-03 2010-06-10 Integrin expression inhibitor

Country Status (16)

Country Link
US (3) US20040018192A1 (no)
EP (1) EP1258252B1 (no)
JP (1) JP4039856B2 (no)
KR (1) KR100767000B1 (no)
CN (1) CN100356979C (no)
AT (1) ATE464892T1 (no)
AU (1) AU781506B2 (no)
CA (1) CA2399001C (no)
DE (1) DE60141889D1 (no)
ES (1) ES2341843T3 (no)
HU (1) HUP0300544A3 (no)
MX (1) MXPA02007249A (no)
NO (1) NO329158B1 (no)
NZ (1) NZ520299A (no)
RU (1) RU2240826C2 (no)
WO (1) WO2001056607A1 (no)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026867A3 (en) * 2002-09-19 2004-08-05 Schering Corp Imidazopyridines as cyclin dependent kinase inhibitors
WO2005052122A2 (en) * 2003-11-22 2005-06-09 Sloan-Kettering Institute For Cancer Research METHODS FOR CONTROLLING PATHOLOGICAL ANGIOGENESIS BY INHIBITION OF α6β4 INTEGRIN
WO2005094391A2 (en) 2004-04-02 2005-10-13 The Regents Of The University Of California METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH αVβ5 INTEGRIN
US20070082941A1 (en) * 2003-09-10 2007-04-12 Eisai Co., Ltd. Crystalline sulfonamide-containing indole compound and process for preparing the same
US20090143353A1 (en) * 2005-08-17 2009-06-04 Daiichi Sankyo Company, Limited Antifungal bicyclic hetero ring compounds
WO2011011775A1 (en) 2009-07-24 2011-01-27 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avb5 integrin
WO2016087593A1 (en) * 2014-12-05 2016-06-09 Syngenta Participations Ag Novel fungicidal quinolinylamidines
WO2018112215A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2022173805A1 (en) * 2021-02-09 2022-08-18 Triana Biomedicines, Inc. Amide and ether substituted n-(1h-indol-7-yl)benzenesulfonamides and uses thereof
EP4252629A2 (en) 2016-12-07 2023-10-04 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000247949A (ja) 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
CA2395772C (en) 1999-12-28 2010-09-28 Eisai Co., Ltd. Sulfonamide-containing heterocyclic compounds
ES2280502T3 (es) * 2001-02-21 2007-09-16 EISAI R&D MANAGEMENT CO., LTD. Metodo para evaluar el efecto de un inhibidor de la angiogenesis a traves de la inhibicion de la expresion de integrinas.
WO2002070478A1 (en) * 2001-03-06 2002-09-12 Astrazeneca Ab Indolone derivatives having vascular-damaging activity
JPWO2003022271A1 (ja) * 2001-09-05 2004-12-24 エーザイ株式会社 リンパ球活性化抑制剤および自己免疫疾患治療剤
EP1481678A4 (en) * 2002-03-05 2009-12-30 Eisai R&D Man Co Ltd ANTITUMORAL AGENT CONTAINING A SULFONAMIDE-CONTAINING HETEROCYCLIC COMPOUND AND AN ANGIOGENESIS INHIBITOR
CA2784937A1 (en) 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
GB0215650D0 (en) * 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
JP4845380B2 (ja) * 2002-09-19 2011-12-28 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
CA2500492C (en) 2002-11-18 2010-03-16 Solomon Ungashe Aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
WO2005090297A1 (en) * 2004-03-19 2005-09-29 Biotie Therapies Corporation Sulphonamide derivatives
JP5094394B2 (ja) * 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
JP2008540539A (ja) * 2005-05-10 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャンネルの調節因子としての二環系誘導体
WO2007008926A1 (en) 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
US20070135499A1 (en) * 2005-07-11 2007-06-14 Aerie Pharmaceuticals, Inc. Hydrazide compounds
FI20055496A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Kollageenireseptorien alfa-l-domeeniin sitoutuvat modulaattorit
FI20055498A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
EP2068878B1 (en) 2006-09-20 2019-04-10 Aerie Pharmaceuticals, Inc. Rho kinase inhibitors
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
DK2178870T3 (en) * 2007-08-17 2018-10-22 Lg Chemical Ltd INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE
JP2011016723A (ja) * 2007-11-02 2011-01-27 Katayama Kagaku Kogyo Kk 骨及び軟骨形成タンパク質を含有する医薬品及び医療器具
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CA2929545C (en) 2009-05-01 2019-04-09 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US20120196854A1 (en) 2009-10-06 2012-08-02 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition comprising aromatic heterocyclic compound
TWI410408B (zh) * 2010-03-16 2013-10-01 Purzer Pharmaceutical Co Ltd 苯磺醯胺衍生物及其醫藥組合物
CN102199148A (zh) * 2010-03-25 2011-09-28 瑞安大药厂股份有限公司 苯磺酰胺衍生物及其医药组合物
FR2984316B1 (fr) * 2011-12-16 2017-08-11 Oreal Coupleur de structure 7-amino-indole, composition tinctoriale en comprenant, procedes et utilisations.
WO2013126608A1 (en) 2012-02-22 2013-08-29 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors
US9415043B2 (en) 2013-03-15 2016-08-16 Aerie Pharmaceuticals, Inc. Combination therapy
CN104163798A (zh) * 2014-07-29 2014-11-26 苏州康润医药有限公司 3-氨基-8-三氟甲基喹啉的合成方法
CN104098498A (zh) * 2014-07-30 2014-10-15 天津市斯芬克司药物研发有限公司 一种吲唑类化合物及其制备方法
KR102579582B1 (ko) 2015-11-17 2023-09-15 에어리 파마슈티컬즈, 인코포레이티드 키나아제 억제제 및 이의 중간체의 제조 방법
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
AU2017319520A1 (en) 2016-08-31 2019-03-07 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
AU2018243687C1 (en) 2017-03-31 2020-12-24 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CA3083228A1 (en) * 2017-12-14 2019-06-20 Dana-Farber Cancer Institute, Inc. Small molecule degraders that recruit dcaft15
SG11202004260YA (en) 2017-12-15 2020-06-29 Bayer Animal Health Gmbh Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives
AU2019211383A1 (en) 2018-01-25 2020-06-11 Dana-Farber Cancer Institute, Inc. Sulfonamide derivatives for protein degradation
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
JP7214882B2 (ja) 2018-10-30 2023-01-30 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体
SG11202103484RA (en) 2018-10-30 2021-05-28 Gilead Sciences Inc Quinoline derivatives as alpha4beta7 integrin inhibitors
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
WO2022173727A1 (en) * 2021-02-09 2022-08-18 Celgene Corporation Sulfonamides and their use for treatment of helminthic infections and diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721246A (en) * 1993-09-10 1998-02-24 Eisai Co., Ltd. Heterobicyclic sulfonamide and sulfonic ester derivatives
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
US5773646A (en) * 1996-03-29 1998-06-30 G. D. Searle & Co. Meta-substituted phenylene derivatives
US5843906A (en) * 1996-03-29 1998-12-01 G. D. Searle & Co. Meta-substituted phenylene sulphonamide derivatives

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9115160D0 (en) 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
HU224069B1 (hu) * 1993-09-10 2005-05-30 Eisai Co. Ltd. Heterobiciklusos szulfonamid-származékok, eljárás előállításukra, ezeket hatóanyagként tartalmazó gyógyászati készítmények, valamint alkalmazásuk gyógyászati készítmények előállítására
US5574018A (en) 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins
JP3690831B2 (ja) * 1995-02-27 2005-08-31 エーザイ株式会社 インドール含有スルホンアミド誘導体
DE69713582T2 (de) * 1996-03-29 2003-01-09 Searle & Co Zimtsäurederivate und deren verwendung als integrin-antagonisten
AU2323897A (en) * 1996-03-29 1997-10-22 G.D. Searle & Co. Cyclopropyl alkanoic acid derivatives
EP0891325B1 (en) * 1996-03-29 2002-02-06 G.D. Searle & Co. Para-substituted phenylpropanoic acid derivatives as integrin antagonists
AU6696698A (en) * 1997-03-11 1998-09-29 Allergan Sales, Inc. Anti-angiogenic agents
EP0973396A4 (en) * 1997-04-07 2001-02-07 Merck & Co Inc METHOD FOR TREATING CANCER
EP0991619B1 (en) * 1997-06-23 2003-09-10 Tanabe Seiyaku Co., Ltd. Inhibitors of alpha 4-beta 1 mediated cell adhesion
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
EP1054871A2 (en) * 1998-04-01 2000-11-29 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
KR20010042704A (ko) * 1998-04-16 2001-05-25 데이비드 비. 맥윌리암스 인테그린이 인테그린 수용체에 결합하는 것을 억제하는ｎ,ｎ-이치환된 아미드
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
JP2002533387A (ja) * 1998-12-23 2002-10-08 ジー．ディー．サール ＆ カンパニー 腫瘍治療の複合療法としてインテグリン拮抗物質と一つ以上の抗腫瘍剤を使用する方法
US6291503B1 (en) * 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
JP2000247949A (ja) * 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721246A (en) * 1993-09-10 1998-02-24 Eisai Co., Ltd. Heterobicyclic sulfonamide and sulfonic ester derivatives
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
US5773646A (en) * 1996-03-29 1998-06-30 G. D. Searle & Co. Meta-substituted phenylene derivatives
US5843906A (en) * 1996-03-29 1998-12-01 G. D. Searle & Co. Meta-substituted phenylene sulphonamide derivatives

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026867A3 (en) * 2002-09-19 2004-08-05 Schering Corp Imidazopyridines as cyclin dependent kinase inhibitors
US6992080B2 (en) 2002-09-19 2006-01-31 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
US20060030555A1 (en) * 2002-09-19 2006-02-09 Schering Corporation Novel imidazopyridines as cyclin dependent kinase inhibitors
US7452902B2 (en) 2002-09-19 2008-11-18 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
US20090247768A1 (en) * 2003-09-10 2009-10-01 Keiko Takahashi Crystalline sulfonamide-containing indole compound and process for preparing the same
US20070082941A1 (en) * 2003-09-10 2007-04-12 Eisai Co., Ltd. Crystalline sulfonamide-containing indole compound and process for preparing the same
US7754894B2 (en) * 2003-09-10 2010-07-13 Eisai R&D Management Co., Ltd. Crystalline sulfonamide-containing indole compound and process for preparing the same
WO2005052122A2 (en) * 2003-11-22 2005-06-09 Sloan-Kettering Institute For Cancer Research METHODS FOR CONTROLLING PATHOLOGICAL ANGIOGENESIS BY INHIBITION OF α6β4 INTEGRIN
WO2005052122A3 (en) * 2003-11-22 2005-08-18 Sloan Kettering Inst Cancer METHODS FOR CONTROLLING PATHOLOGICAL ANGIOGENESIS BY INHIBITION OF α6β4 INTEGRIN
US20070104716A1 (en) * 2003-11-22 2007-05-10 Sloan-Kettering Institute For Cancer Research Methods for controlling pathological angiogenesis by inhibition of a6b4 integrin
US7815908B2 (en) 2004-04-02 2010-10-19 Regents Of The University Of California Methods and compositions for treating and preventing disease associated with αVβ5 integrin
EP2394662A2 (en) 2004-04-02 2011-12-14 The Regents of The University of California Methods and compositions for treating and preventing disease associated with AlphavBeta5 intergrin
WO2005094391A2 (en) 2004-04-02 2005-10-13 The Regents Of The University Of California METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH αVβ5 INTEGRIN
US20090280118A1 (en) * 2004-04-02 2009-11-12 The Regents Of The University Of California METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH alphaVbeta5 INTEGRIN
US7737166B2 (en) 2005-08-17 2010-06-15 Daiichi Sankyo Company, Limited Antifungal bicyclic hetero ring compounds
US20090143353A1 (en) * 2005-08-17 2009-06-04 Daiichi Sankyo Company, Limited Antifungal bicyclic hetero ring compounds
US10087252B2 (en) 2009-07-24 2018-10-02 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with αvβ5 integrin
WO2011011775A1 (en) 2009-07-24 2011-01-27 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avb5 integrin
WO2016087593A1 (en) * 2014-12-05 2016-06-09 Syngenta Participations Ag Novel fungicidal quinolinylamidines
EP4252629A2 (en) 2016-12-07 2023-10-04 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112215A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
EP4233902A2 (en) 2016-12-14 2023-08-30 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020106750A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2022173805A1 (en) * 2021-02-09 2022-08-18 Triana Biomedicines, Inc. Amide and ether substituted n-(1h-indol-7-yl)benzenesulfonamides and uses thereof

Also Published As

Publication number Publication date
US7834049B2 (en) 2010-11-16
ES2341843T3 (es) 2010-06-29
DE60141889D1 (de) 2010-06-02
AU2886701A (en) 2001-08-14
HUP0300544A2 (hu) 2003-07-28
NZ520299A (en) 2004-05-28
EP1258252A4 (en) 2005-11-02
NO20023688L (no) 2002-10-03
HUP0300544A3 (en) 2005-03-29
MXPA02007249A (es) 2002-12-09
CA2399001A1 (en) 2001-08-09
NO329158B1 (no) 2010-08-30
KR100767000B1 (ko) 2007-10-15
RU2002123580A (ru) 2004-03-20
US20050176712A1 (en) 2005-08-11
EP1258252A1 (en) 2002-11-20
AU781506B2 (en) 2005-05-26
CN100356979C (zh) 2007-12-26
WO2001056607A1 (fr) 2001-08-09
CN1396833A (zh) 2003-02-12
EP1258252B1 (en) 2010-04-21
ATE464892T1 (de) 2010-05-15
KR20020073575A (ko) 2002-09-27
JP4039856B2 (ja) 2008-01-30
NO20023688D0 (no) 2002-08-02
US20100267754A1 (en) 2010-10-21
RU2240826C2 (ru) 2004-11-27
CA2399001C (en) 2010-07-20

Similar Documents

Publication Publication Date Title
US7834049B2 (en) Integrin expression inhibitor
JP4234344B2 (ja) スルホンアミド含有複素環化合物
JP3545461B2 (ja) 二環式ヘテロ環含有スルホンアミド誘導体
CN101253166B (zh) 磺酰胺化合物
EP0673937B1 (en) Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives
WO2006080450A1 (ja) Igf-1r阻害剤
BRPI0707028A2 (pt) método para alcaçar um efeito em um paciente, composto e composição farmacêutica
WO2002032872A1 (en) Nitrogenous aromatic ring compounds
JP2000514806A (ja) プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
CZ289249B6 (cs) Amidy a farmaceutické prostředky na jejich bázi
SK10802003A3 (sk) Kondenzovaná heterocyklická zlúčenina, jej použitie a jej farmaceutický prípravok
WO2019101086A1 (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
JP2008526702A (ja) 置換オキシインドール誘導体、該誘導体を含んでいる薬物及びそれらの使用
BG99879A (bg) Инхибитори на нiv реверсивна транскриптаза
CN107098846A (zh) N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途
JP2000517301A (ja) テトラヒドロイソキノリン誘導体およびそれらの薬理学的使用
JP4007743B2 (ja) 血管新生阻害剤
JP2008514572A (ja) 可溶性アデニル酸シクラーゼのインヒビターとしてのインドール誘導体
KR100767002B1 (ko) 인테그린 발현 저해제
EP4066895A1 (en) Compound having lysophosphatidic acid receptor agonistic activity and pharmaceutical use of said compound
WO2001023349A1 (fr) Derives d'acylsulfonamide
MX2008006653A (en) Thrombopoietin activity modulating compounds and methods

Legal Events

Date Code Title Description
AS Assignment

Owner name: EISAI CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WAKABAYASHI, TOSHIAKI;FUNAHASHI, YASUHIRO;HATA, NAOKO;AND OTHERS;REEL/FRAME:013233/0952

Effective date: 20020625

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION